Oestradiol concentration and the development of the uterine oxytocin receptor and oxytocin-induced PGF2 alpha release in ewes.
The control of temporal changes in oxytocin receptor concentrations and oxytocin-induced 13,14-dihydro-15-keto PGF2 alpha (PGFM) release was examined in ewes. One week after ovariectomy, 36 ewes were administered fluorogesterone acetate for 10 days followed by oestradiol (3 x 16 micrograms day-1) for 2 days (pretreatment cycle). Day 0 was designated as the time of the final 'oestrous' oestradiol injection. Ewes were then treated for up to 12 days with progesterone (24 mg day-1 maximum) with or without oestradiol (both hormones administered in 1 ml of corn oil i.m. at 8 h intervals) in a pattern known to simulate natural plasma profiles of the oestrous cycle. The three treatments were zero oestradiol, low oestradiol (12 micrograms day-1 maximum), and high oestradiol (36 micrograms day-1 maximum). Subgroups of four ewes from each treatment group were given 1 microgram of oxytocin (i.v.) on day 10, 11 or 12 of the simulated cycle, and endometrial oxytocin receptor concentrations were determined in samples collected within 3 h of oxytocin administration. On day 10 only one ewe in each group exhibited a PGFM response to oxytocin, and the mean response was unaffected by the concentration of oestradiol administered. On days 11 and 12 there was a significant effect of oestradiol concentration (P < 0.05) on the pattern of PGFM release in response to oxytocin, the high oestradiol concentration causing a rapid increase in the concentration of PGFM following oxytocin administration. On day 12 the oestradiol concentration was positively correlated with the PGFM mean response (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
AFRC Research Group on Hormones and Farm Animal Reproduction, Faculty of Agricultural and Food Sciences, University of Nottingham, UK.
A P
AP
Beard
G E
GE
Lamming
D000818:Animals; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism* / Q000494:pharmacology; D005260:Female; D010052:Ovariectomy; D010121:Oxytocin / Q000378:metabolism*; D018045:Receptors, Oxytocin / Q000187:drug effects / Q000378:metabolism*; D012756:Sheep / Q000378:metabolism*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D018045:Receptors, Oxytocin; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost